• CVS Health reported past first-quarter 2026 results with revenue of at least US$100.43 billion and net income of US$2.94 billion, alongside higher earnings guidance for the full year.
• Management attributed the stronger performance and raised outlook to improved profitability in the Aetna insurance and pharmacy segments, aided by updated pharmacy reimbursement and margin recovery efforts.
• We’ll now examine how CVS Health’s stronger Aetna insurance profitability and upgraded 2026 earnings guidance influence the company’s investment narrative.

This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

CVS Health Investment Narrative Recap

To own CVS Health, you need to believe its integrated model across insurance, pharmacy and care delivery can translate margin recovery into durable earnings, despite thin current profit margins and ongoing cost pressure. The latest quarter’s stronger Aetna profitability and raised 2026 earnings guidance support that thesis in the near term, while also easing (but not eliminating) concerns about elevated medical costs and reimbursement pressure as the key short term catalyst and risk.

Among recent announcements, the July 1, 2026 CVS Caremark formulary updates to favor lower cost biosimilars stand out. These changes tie directly into the margin recovery and cost-control story behind the upgraded 2026 outlook, and may matter for how CVS balances affordability for members with the need to stabilize pharmacy and insurance profitability over time.

But while guidance is higher, investors should also be aware of the risk that elevated medical cost trends and reimbursement pressure could still...

CVS Health’s narrative projects $445.1 billion revenue and $10.3 billion earnings by 2029. This requires 3.6% yearly revenue growth and a roughly $8.5 billion earnings increase from $1.8 billion today.

Uncover how CVS Health's forecasts yield a $96.58 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span roughly US$97 to US$273 per share, showing how far apart individual views can be. When you set those against CVS’s improved Aetna margins and higher 2026 earnings guidance, it underlines why many readers may want to compare several different expectations for how sustainable this recovery really is.

Explore 5 other fair value estimates on CVS Health - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CVS Health research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.